Revumenib in Combination With 7+3 + Midostaurin in AML

Clinical trial NCT06313437 · RECRUITING

Trial details

NCT number: NCT06313437
Sponsor: Richard Stone, MD
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia AML, Adult AML With Gene Mutations AML Leukemia

Start date: 2024-12-06
Primary completion: 2027-03-02
Enrollment: 22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.